The FDA has granted Emergency Use Authorisation (EUA) to Regeneron’s antibody cocktail for COVID-19. The cocktail combines casirivimab and imdevimab administered together is the first combination therapy to receive this...

FairJourney Biologics enters antibody discovery agreement with Pandion Therapeutics

FairJourney Biologics S.A (FJB) and IONTAS Limited (IONTAS), leaders in the discovery and optimization of VHH and fully human antibodies, have signed an agreement...

Beckman Coulter launch SARS-CoV-2 IgM antibody test in countries accepting CE Mark

Beckman Coulter, a clinical diagnostics leader, has announced the launch of its Access SARS-CoV-2 Immunoglobulin M (IgM) assay in countries accepting the CE Mark. The...

View the Online Magazine

- Advertisement -

Launches

Beckman Coulter launch SARS-CoV-2 IgM antibody test in countries accepting CE Mark

Beckman Coulter, a clinical diagnostics leader, has announced the launch of its Access SARS-CoV-2 Immunoglobulin M (IgM) assay in countries accepting the CE Mark. The...

The Native Antigen Company launches range of SARS-CoV-2 specific antibodies

The Native Antigen Company (now part of LGC’s Clinical Diagnostics Division), suppliers of reagents that enable research into vaccines and diagnostics for emerging and...

New saliva-based COVID-19 test promises results in ten minutes

A saliva-based lateral flow COVID-19 test which promises results in ten minutes has launched in the UK. The Rapid Saliva Protein Test (RSPT) from Medusa...

Suppliers Guide

Check out our Suppliers Guide or contact our team and get your company listed

Subscribe

Keep up with what's happening in the industry and subscribe to our weekly newsletter

Events

Get your event seen by potential candidates on the world's leading industry site.

Supply Chain

Life sciences accelerator creates seventy new companies since inception

MediCity Glasgow, a multi-agency supported incubator & accelerator project, has helped create seventy new life sciences and med-tech companies in the last five years,...

Avacta launch COVID-19 laboratory test

Avacta Group is set to launch a high-performance test for the SARS-CoV-2 spike protein to support global efforts to combat COVID-19. Enzyme linked immunosorbent assays...

US secures 100m doses of Moderna’s COVID-19 mRNA vaccine

The US government has secured 100 million doses of Moderna’s mRNA vaccine against COVID-19. The government has paid Moderna, the Cambridge, UK-based biotech pioneering mRNA...

In brief: Sanofi & GSK in talks to supply 300m doses of COVID vaccine to EU

Sanofi and GlaxoSmithKline (GSK) are in “advanced discussions” with the European Commission (EC) for the supply of up to 300 million doses of a...

Approvals

Regeneron’s antibody cocktail granted Emergency Use Authorisation

The FDA has granted Emergency Use Authorisation (EUA) to Regeneron’s antibody cocktail for COVID-19. The cocktail combines casirivimab and imdevimab administered together is the first...

RedHill’s second COVID candidate cleared in US for phase 2/3 study

The US FDA has cleared RedHill Biopharma’s Investigational New Drug (IND) application for a Phase 2/3 study evaluating orally administered RHB-107 (upamostat) in patients...

European approval for Tecentriq-Avastin combo for HCC

The European Commission has approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma...

FDA grants approval to broaden indication for Totect®

The FDA has granted approval to broaden the indication for Totect® to now include reducing the incidence and severity of cardiomyopathy associated with doxorubicin...

Orphan designation for Novartis’ branaplam in Huntington’s disease

Novartis’ branaplam (LMI070) has gained Orphan Drug Designation in the US in Huntington’s disease (HD). In preclinical models, branaplam has been shown to reduce levels...

Forxiga recommended for approval in the EU for heart failure

AstraZeneca’s Forxiga (dapagliflozin) has been recommended for an indication extension of its marketing authorisation in the European Union (EU) for the treatment of symptomatic...

Manufacturiung

Finance

BMS completes $13bn MyoKardia acquisition

Bristol Myers Squibb (BMS) has completed its $13.1 billion acquisition of MyoKardia. “We are excited to welcome MyoKardia colleagues to Bristol Myers Squibb,” said BMS...

Adagio raises $80m to advance antibodies for coronaviruses

Adagio Therapeutics has raised $80 million to further advance best-in-class antibodies for SARS-CoV-2, SARS-CoV-1, and additional potentially emergent coronaviruses. The funding round was led by...

Merck bolsters oncology pipeline with $2.75bn VelosBio acquisition

Merck is strengthening its oncology pipeline with the $2.75 billion acquisition of San Diego biopharma, VelosBio. VelosBio is a privately held clinical-stage biopharmaceutical company committed...

Sanofi offers to acquire Dutch cell-based immunotherapy specialist, Kiadis

Sanofi has offered to acquire Kiadis, a Dutch clinical-stage company developing cell-based immunotherapy products for €308 million. Kiadis’ proprietary platform is based on allogeneic or...

Research & Development
Latest

FairJourney Biologics enters antibody discovery agreement with Pandion Therapeutics

FairJourney Biologics S.A (FJB) and IONTAS Limited (IONTAS), leaders in the discovery and optimization of VHH and fully human antibodies, have signed an agreement...

95% efficiency for Pfizer & BioNTech’s mRNA-based COVID vaccine candidate

Pfizer and BioNTech’s mRNA-based COVID-19 vaccine candidate – BNT162b2 – has achieved an efficiency rate of 95% after hitting all primary endpoints in a...

Lead Pharma and Roche to develop oral small molecules for immune mediated diseases

Lead Pharma has entered into a collaboration and license agreement with Roche to develop oral small molecules to treat a broad range of immune...

New Timestrip indicators track coronavirus vaccines

Timestrip®, the developer of smart indicator technology, has released two new ranges designed to be used with the latest coronavirus vaccines now becoming available. The...

Moderna’s COVID-19 vaccine candidate 95% efficient in phase 3 study

Moderna’s COVID-19 vaccine candidate has achieved efficiency of almost 95% in a Phase 3 study. This COVE study enrolled more than 30,000 participants in the...

Appointments

ACG promotes Susheel Pillai as the new CEO for Inspection Business

ACG, a leading supplier of fully integrated solutions to the global pharmaceutical and nutraceutical industry, today announced the promotion of Susheel Pillai as the new...

New Chief Medical Officer for Valneva

Valneva, a specialty vaccine company based in France, has appointed Juan Carlos Jaramillo, as Chief Medical Officer and member of the Management Board. Starting 1st...

In brief: New head of R&D for Cellbox Solutions

Germany’s Cellbox Solutions has appointed Lonza Pharma and Biotech’s former Head of Biosolutions R&D as its new Head of R&D. Dr Herbert A. Mueller-Hartmann will...
- Advertisement -

FDA grants approval to broaden indication for Totect®

The FDA has granted approval to broaden the indication for Totect® to now include reducing the incidence and severity of cardiomyopathy associated with doxorubicin...

Orphan designation for Novartis’ branaplam in Huntington’s disease

Novartis’ branaplam (LMI070) has gained Orphan Drug Designation in the US in Huntington’s disease (HD). In preclinical models, branaplam has been shown to reduce levels...